Sareum Holdings plc (LON:SAR – Get Free Report)’s share price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 26.09 ($0.32) and traded as low as GBX 22.25 ($0.28). Sareum shares last traded at GBX 23 ($0.28), with a volume of 182,731 shares.
Sareum Stock Down 0.7 %
The company’s 50-day simple moving average is GBX 26.09 and its 200 day simple moving average is GBX 28.85. The firm has a market capitalization of £24.13 million, a PE ratio of -372.50 and a beta of -1.08.
Sareum Company Profile
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Read More
- Five stocks we like better than Sareum
- Short Selling – The Pros and Cons
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- What is the Australian Securities Exchange (ASX)
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Best Stocks Under $10.00
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
